2022 World Conference on Lung Cancer (ePosters)-EP08.01-062. Body Mass Index, Immune Related Adverse Events, and Survival in Patients with Metastatic Non-small Cell Lung Cancer Treated with Immunotherapy

EP08.01-062. Body Mass Index, Immune Related Adverse Events, and Survival in Patients with Metastatic Non-small Cell Lung Cancer Treated with Immunotherapy

Back to course

Pdf Summary

A recent study conducted at The Ohio State University Comprehensive Cancer Center investigated the relationship between body mass index (BMI), immune-related adverse events (irAEs), and overall survival (OS) in patients with metastatic non-small cell lung cancer (NSCLC) who were treated with immunotherapy. The study aimed to determine the impact of obesity, a known risk factor for cancer, on immunotherapy outcomes.<br /><br />The researchers hypothesized that obesity may alter immunotherapy response due to its effects on drug pharmacokinetics and pharmacodynamics, as well as its role in androgen metabolism, which has been linked to T-cell exhaustion. They retrospectively analyzed data from 460 patients with stage IV NSCLC who received immune checkpoint inhibitor treatment between 2011 and 2020. Patient characteristics, including BMI, were obtained from electronic chart review.<br /><br />The results showed that a higher BMI was associated with significantly improved OS compared to normal BMI. Patients with a BMI of 40 had the lowest risk of death among all the BMI groups studied. Developing any grade irAE was also associated with improved OS. However, in this cohort, BMI was not found to be associated with the development of irAEs in general.<br /><br />The study concluded that obesity, as measured by BMI, is closely linked to immunotherapy response in patients with metastatic NSCLC. Higher BMI was associated with longer median OS and a decreased hazard of death. The findings suggest that obesity may have complex effects on immune function and response to immunotherapy.<br /><br />The study acknowledges the need for larger cohorts and more data to validate these findings. Nevertheless, this research contributes to our understanding of the impact of obesity on cancer treatment outcomes and highlights the potential importance of personalized treatment approaches based on patients' BMI. The study was supported by the National Institutes of Health and the research resources at The Ohio State University. For further information, the authors can be contacted via the provided email addresses.

Asset Subtitle

Mingjia Li

Meta Tag

Speaker Mingjia Li

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

Ohio State University Comprehensive Cancer Center

body mass index

BMI

immune-related adverse events

irAEs

overall survival

metastatic non-small cell lung cancer

NSCLC

immunotherapy

obesity